Scientists discover new ARDS treatment pathway via immune cell modulation

Researchers have uncovered a new biological pathway that could help treat acute respiratory distress syndrome (ARDS). The study, published in Cell Death Discovery, was led by Lv, Jiang, Zhang, and their team. It highlights how the sympathetic nervous system influences immune cells in the lungs during severe injury. ARDS is a life-threatening condition marked by severe inflammation, alveolar damage, and impaired gas exchange. The condition often results in respiratory failure. The study found that activation of the sympathetic nervous system modulates macrophage function in injured lungs.

The pathway involves β-adrenergic receptors on macrophages. When stimulated, these receptors increase the expression and activity of histidine decarboxylase (HDC). This, in turn, boosts the function of the cystine/glutamate antiporter subunit SLC7A11. Together, HDC and SLC7A11 enhance antioxidant defences in macrophages, reducing oxidative stress and inflammation.

Experiments in animal models showed promising results. Mimicking sympathetic activation or pharmacologically upregulating the HDC/SLC7A11 pathway improved lung tissue structure, oxygenation, and survival rates. The findings suggest potential new treatments for ARDS by targeting this pathway. Further research will explore the specific receptor subtypes and long-term effects of modulating the HDC/SLC7A11 axis in chronic lung diseases. The implications may also extend to other inflammatory and infectious conditions linked to macrophage dysfunction.